使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
(audio in progress)
(音訊正在播放)
And we look forward to bringing this unique catheter to the US. Beyond CAS, we're also making (technical difficulty) material progress with Symplicity Spyral for hypertension and Altaviva for urge urinary incontinence.
我們期待將這種獨特的導管引入美國。除了CAS之外,我們在治療高血壓的Symplicity Spyral和治療急迫性尿失禁的Altaviva方面也取得了實質進展(儘管技術難度較高)。
Symplicity delivers a one-time, durable, minimally invasive treatment for hypertension and represents one of our largest growth drivers. Now this is going to be a contributor for years to come, given the 18 million US patients with uncontrolled hypertension. We're seeing strong patient outcomes in the field, and the already in value proposition, it resonates with both physicians and patients. We're seeing strong patient outcomes in the field, and the [RD] in value proposition, it resonates with both physicians and patients.
Symplicity 為高血壓患者提供一次性、持久、微創的治療方案,是我們最大的成長動力之一。鑑於美國有 1800 萬高血壓患者未得到控制,這將在未來幾年成為一個影響因素。我們看到該領域取得了良好的患者療效,而且其現有的價值主張也引起了醫生和患者的共鳴。我們看到該領域取得了良好的患者療效,而[RD]的價值主張引起了醫生和患者的共鳴。
Now we've got strong and growing clinical data, a broad label, and expanding reimbursement all in hand. Look, we've built the foundation. Now we're focused on growing this new segment and transforming the hypertension treatment paradigm. We've recently activated our direct-to-consumer Go Beyond campaign in key markets around the US which is resulting in a 50 times increase in website visits versus the prior quarter, so a lot of interest coming in from patients.
現在我們掌握了強大且不斷增長的臨床數據、廣泛的適應症和不斷擴大的報銷範圍。你看,我們已經打好基礎了。現在我們專注於發展這一新領域,並改變高血壓治療模式。我們最近在美國主要市場啟動了面向消費者的「超越」行銷活動,與上一季相比,網站訪問量增加了 50 倍,因此患者對此表現出了濃厚的興趣。
Building a new market, it does take time. That is something Medtronic knows how to do exceptionally well. And in parallel to building out this new market, we're innovating for the long-term. First with our transradial catheter, which is on track to launch in the second half of fiscal year '27, and with our SPYRAL GEMINI trial evaluating multi-organ ablation to further boost efficacy.
建立新市場確實需要時間。美敦力在這方面做得非常出色。在開拓這個新市場的同時,我們也進行長期的創新。首先是我們的經橈動脈導管,預計將於 2027 財年下半年推出;其次是我們的 SPYRAL GEMINI 試驗,該試驗評估多器官消融術,以進一步提高療效。
Now, similarly, we are scaling Altaviva. Our tibial neurostimulation device. Altaviva is a is a simple yet transformational option for treating urge urinary incontinence, which is a condition that affects 16 million people in the US. Altaviva is a very small device that requires no imaging, no sedation, activates the same day, is MRI ready, and offers up to 15 years of battery life, the longest in its category. Again, we are receiving great early interest and feedback from both physicians and patients, and we are training doctors, we're educating and supporting hospital staff, and investing in online channel consumer activation. Look, it's early days for both of these launches, and we are focused on disciplined execution to convert early traction into procedures.
現在,我們也以類似的方式擴展 Altaviva 的規模。我們的脛神經刺激裝置。Altaviva 是一種簡單而又具有變革性的治療尿急性尿失禁的方法,影響著美國 1600 萬人。Altaviva 是一款非常小的設備,無需成像,無需鎮靜,當天即可激活,可用於 MRI 檢查,電池壽命長達 15 年,是同類產品中最長的。再次強調,我們收到了來自醫生和患者的巨大早期興趣和回饋,我們正在培訓醫生,教育和支持醫院工作人員,並投資於線上通路消費者活化。你看,這兩個專案都還處於早期階段,我們專注於嚴謹的執行,將早期的進展轉化為實際操作流程。
Now pivoting to Hugo. This quarter, our Hugo, robot received FDA clearance for urologic surgical procedures, enabling us to begin our purposeful US launch. And today, I'm excited to share that we've already completed our first installations and initial cases. As noted in our release this morning, last week we completed our first cases at Cleveland Clinic, where surgeons echoed the strong feedback we continuously receive on Hugo's differentiation across multiple areas. This includes its flexibility, portability, open console, and of course, our trusted instrumentation.
現在轉向雨果。本季度,我們的 Hugo 機器人獲得了 FDA 批准,可用於泌尿外科手術,使我們能夠開始有目的地在美國上市。今天,我很高興地宣布,我們已經完成了首批安裝和初步案例。正如我們今天早上發布的新聞稿中所述,上週我們在克利夫蘭診所完成了首批手術,外科醫生們也對我們不斷收到的關於 Hugo 在多個領域差異化的強烈反饋表示贊同。這包括它的靈活性、便攜性、開放式控制台,當然還有我們值得信賴的儀器。
Hugo is especially compelling when paired with our Touch Surgery digital ecosystem, an AI powered data, connectivity and analytics technology that is unique to Medtronic. This quarter, Touch Surgery installations increased over 20% sequentially and have now surpassed 1,000 systems globally. Further, we continue to evolve our Hugo system with the fourth-generation software release and continuous system improvements. We are planning to expand into additional indications in the US like hernia, part of our broader general surgery indication where this system really shines.
Hugo 與我們的 Touch Surgery 數位生態系統(美敦力獨有的 AI 驅動的數據、連接和分析技術)結合使用時,其吸引力尤其顯著。本季度,Touch Surgery 的安裝量較上季成長超過 20%,目前全球系統數量已超過 1,000 套。此外,我們透過第四代軟體版本和持續的系統改進,不斷發展我們的 Hugo 系統。我們計劃將該系統擴展到美國的其他適應症,例如疝氣,這是我們更廣泛的普通外科適應症的一部分,而該系統在這個領域真正發揮了優勢。
Customer value, I mean they really value having a partner that spans the full continuum of surgical care and Medtronic is the only company that has approved offerings across open, laparoscopic, and robotic assisted surgeries, which matters as hospitals build and expand. Now, we are thrilled with these four generational growth drivers. But our innovation pipeline is far broader, and we are committed to driving sustained innovation across our portfolio and advancing a steady cadence of new technologies across high need, high growth categories we are well positioned. Like MMA, carotid stenting, thrombectomy, coronary DCB, cardiac rhythm management, spine surgery, as well as many others.
客戶價值,我的意思是,他們非常重視擁有一個能夠涵蓋整個外科護理領域的合作夥伴,而美敦力是唯一一家在開放式手術、腹腔鏡手術和機器人輔助手術方面擁有獲批產品的公司,這對於醫院的建設和擴張至關重要。現在,我們對這四大世代成長驅動因素感到非常興奮。但我們的創新管道更加廣泛,我們致力於推動產品組合的持續創新,並在我們佔據優勢的高需求、高成長領域穩步推進新技術。就像 MMA、頸動脈支架置放術、血栓切除術、冠狀動脈藥物塗層球囊擴張術、心臟節律管理、脊椎手術以及其他許多手術一樣。
And to that point, I'm extremely excited to highlight a major milestone in our neuroscience business. Just last week, we secured FDA clearance for our Stealth AXiS Surgical System for spinal procedures. Stealth AXiS is a new transformative platform that unifies AI power planning, robotics, and navigation into one seamless system elevated by the entire AiBLE ecosystem. Stealth AXiS was designed around navigation, which is paramount to surgeons workflow in the OR. Today, navigation, which we pioneered and we lead, drives 70% of US spine procedures and really it just dictates the workflow in the spine OR. So Stealth is really two things. It's about taking share as a new platform with improved functionality and it brings down barriers for physicians to step into robotics without disrupting their workflow.
在此,我非常激動地向大家介紹我們神經科學業務的一個重要里程碑。就在上週,我們的 Stealth AXiS 手術系統獲得了 FDA 批准,可用於脊椎手術。Stealth AXiS 是一個全新的變革性平台,它將 AI 電源規劃、機器人和導航統一到一個無縫系統中,並由整個 AiBLE 生態系統提升。Stealth AXiS 的設計以導航為核心,這對於外科醫生在手術室的工作流程至關重要。如今,我們率先研發並引領的導航技術,驅動著美國 70% 的脊椎手術,它實際上決定了脊椎手術室的工作流程。所以,隱身其實包含兩面。它旨在透過改進功能,以新平台的形式佔據市場份額,並降低醫生進入機器人領域的門檻,同時又不擾亂他們的工作流程。
Now, building on our 10,000 unit installed base, we are expanding and opening this segment and extending our leadership. And we're not stopping at spine. We anticipate pursuing future cranial and ENT indications for Stealth AXiS. This is an important driver for our CST business and an exciting step forward to improve precision, predictability and personalization of care.
現在,憑藉我們10,000台的裝機量,我們正在拓展和開拓這一細分市場,並鞏固我們的領先地位。我們並不會止步於脊椎。我們預計未來將探索 Stealth AXiS 在顱腦和耳鼻喉科的適應症。這是對我們 CST 業務的重要推動力,也是提高護理的精確性、可預測性和個人化的令人興奮的一步。
And we're executing our M&A strategy as well, and we continue to build out our venture and minority investment portfolio with the Anteris Investment and Structural Heart. Both transactions underscore our long-term strategy to digitize, enable, and build effective and efficient ecosystems within our core markets.
我們也正在執行併購策略,並透過 Anteris Investment 和 Structural Heart 繼續拓展我們的創投和少數股權投資組合。這兩筆交易都凸顯了我們在核心市場內實現數位化、賦能和建構高效生態系統的長期策略。
So before I turn it over to Thierry to walk through the details of our business performance, our financials, and the guidance; I would like to close with the following remarks.
因此,在我把發言權交給 Thierry 來詳細介紹我們的業務表現、財務狀況和業績指引之前,我想以以下幾點作為結尾。
At Medtronic, we are translating the breadth and the depth of innovation across the portfolio, into durable growth. We have businesses at different stages of their growth journey but the cadence of innovation across our portfolio suggests a steadily improving growth outlook for total Medtronic.
在美敦力,我們正在將產品組合中廣度和深度的創新轉化為永續成長。我們旗下各業務處於不同的發展階段,但我們產品組合中的創新節奏表明,美敦力整體的成長前景正在穩步改善。
We have businesses that are executing exceptionally well today in our position to be meaningful contributors for a very long time. This includes CAS with its strong PFA pipeline, CST with self-access, and of course CRM, a large and steady growth engine with meaningful innovation and defibrillation and leadless and a conduction system pacing.
我們旗下的一些業務目前營運狀況非常出色,這使我們有能力在很長一段時間內繼續做出有意義的貢獻。這其中包括擁有強大 PFA 產品線的 CAS、擁有自主存取功能的 CST,當然還有 CRM,這是一個規模龐大且穩定成長的引擎,具有有意義的創新以及除顫、無導線和傳導系統起搏功能。
We have businesses where the pipeline is now just activating, where we have clear line of sight to meaningful tangible opportunities that will enhance growth. From CRDN with the ramp of Symplicity, pelvic health with Altaviva, peripheral vascular health with Neuroguard and Liberant, and neurovascular with innovation like Artisse, Neuroguard, and expanding indication for Onyx into MMAe. And surgical, where the launch of Hugo in the US is just beginning.
我們有一些業務,其發展管道目前才剛剛啟動,我們已經清楚地看到了能夠促進成長的有意義的實際機會。從 CRDN(透過 Symplicity 的斜坡)、骨盆底健康(透過 Altaviva)、週邊血管健康(透過 Neuroguard 和 Liberant)、神經血管(透過 Artisse、Neuroguard 等創新)到神經血管,以及 Onyx 的適應症擴展到 MMAe。而外科手術方面,Hugo 在美國的推出才剛開始。
These are all real drivers with tangible reasons for improvement and the potential to impact growth in the coming quarters and years. We also have areas where there is work to do and we have defined plans underway, like in Structural Heart, where we're taking specific actions to fill out the portfolio and improve the trajectory. So with strong contributors delivering today, businesses on the cusp of step change improvement, and segments where we're taking deliberate actions to strengthen long-term competitiveness, we are confident in our ability to deliver durably.
這些都是切實可行的改進驅動因素,具有在未來幾季和幾年內影響成長的潛力。我們還有一些領域需要改進,我們已經制定了明確的計劃,例如在結構核心領域,我們正在採取具體措施來完善投資組合併改善發展軌跡。因此,憑藉今天表現強勁的貢獻者、即將迎來變革性改進的企業,以及我們正在採取實際行動以增強長期競爭力的領域,我們有信心能夠持續取得成果。
So with that, I'll turn it over to Thierry to walk through the details of our business performance. So over to Thierry.
那麼,接下來就交給蒂埃里,讓他詳細介紹我們的業務表現。接下來請蒂埃里發言。
Thierry Pieton - Chief Financial Officer, Executive Vice President
Thierry Pieton - Chief Financial Officer, Executive Vice President
Hey, thanks, Geoff, and hi, everyone. I appreciate all of you joining today.
嘿,謝謝你,傑夫,大家好。感謝各位今天到場。
Let's start with our cardiovascular portfolio where this quarter we delivered 11% year-over-year revenue growth with 13% growth in the US. This represents the strongest growth we've seen in cardiovascular in the last 10 years, excluding COVID comps. CAS grew 80% year over year, with PFA accounting for 80% of that revenue. Beyond CAS, the remainder of the cardiovascular portfolio delivered combined mid-single-digit growth.
讓我們先來看看我們的心血管產品組合,本季我們實現了 11% 的年成長,其中美國市場成長了 13%。(不包括新冠疫情相關數據)這是過去 10 年來心血管領域最強勁的成長。CAS年增80%,其中PFA貢獻了80%的收入。除了 CAS 之外,其餘心血管產品組合實現了中等個位數的成長。
Cardiac rhythm management also had a strong quarter. CRM continued to contribute 15% of our total revenue and it grew a healthy 5%. This was primarily driven by continued double-digit growth in micro, mid-teens growth in 3830 CSP Lead, and over 70% growth in Aurora EV-ICD.
心臟節律管理業務本季也表現強勁。CRM 繼續貢獻我們總收入的 15%,並實現了 5% 的健康成長。這主要得益於微型企業持續兩位數的成長、3830 CSP Lead 的十幾位數成長以及 Aurora EV-ICD 超過 70% 的成長。
In peripheral vascular health, we posted high-single-digit growth driven by broad strength across our endovenous portfolio. We look forward to the continued launch of Neuroguard IEP carotid stent and the full market release of our Liberant mechanical thrombectomy system.
在周邊血管健康領域,我們實現了接近兩位數的成長,這主要得益於我們靜脈注射產品組合的全面強勁表現。我們期待 Neuroguard IEP 頸動脈支架的持續推出以及 Liberant 機械血栓切除系統的全面上市。
In Structural Heart, Q3 was a little softer as expected and grew low-single-digits. We had a stronger quarter internationally and continued to gain share in Europe. This was partially offset in the US where we annualized our Evolut FX+ launch and saw some competitive pressure.
在結構性心臟病方面,第三季如預期般略微疲軟,成長幅度僅為個位數。我們在國際市場上的表現更加強勁,並持續在歐洲擴大市場份額。這種情況在美國部分得到了抵消,因為我們將 Evolut FX+ 的推出週期縮短至一年,並面臨了一些競爭壓力。
I'll now pivot to our neuroscience portfolio which grew 3%. Growth was a little below our expectations this quarter but neuroscience is also where we have one of our broadest pipelines and some of our most exciting opportunities. Importantly, we expect that pipeline to begin impacting growth in the fourth quarter.
接下來我將重點介紹我們的神經科學投資組合,該組合成長了 3%。本季成長略低於預期,但神經科學領域也是我們擁有最廣泛的研發管線和一些最令人興奮的機會的領域之一。重要的是,我們預計該項目將在第四季度開始對成長產生影響。
Cranial and spinal technologies continues to be a powerful engine for Medtronic. This large business delivered mid-single-digit growth, including 8% growth from strong pull-through in Core Spine. We're excited to offer customers our new navigation and robotics platform, Stealth AXiS, which Geoff just mentioned with FDA clearance achieved, we expect to see Stealth AXiS, contribute neurosurgery, and CST overall as soon as the fourth quarter.
顱腦和脊椎技術仍然是美敦力公司的強大驅動力。這家大型企業實現了中等個位數的成長,其中核心脊椎業務強勁成長帶來了 8% 的成長。我們很高興向客戶提供我們全新的導航和機器人平台 Stealth AXiS,正如 Geoff 剛才提到的,該平台已獲得 FDA 批准,我們預計 Stealth AXiS 最早將於第四季度在神經外科和 CST 領域發揮作用。
Specialty Therapies delivered flat results in the third quarter. This is an area where we expect improved performance in the coming quarters, given the series of new product developments. Neurovascular has been challenged over the last quarters due to China VBP and to the recall of Vantage, both of which are now mostly behind us. We also have line of sight to a higher level of growth from the contribution of Onyx's expanded indication. The Neuroguard carotid stent launch will also contribute as it's being commercialized by both our neurovascular and peripheral vascular businesses.
專科治療業務第三季業績持平。鑑於一系列新產品的開發,我們預計未來幾季該領域的業績將有所改善。過去幾個季度,由於中國 VBP 計畫和 Vantage 的召回,神經血管業務面臨挑戰,但這兩件事現在大多已經過去了。我們也看到了Onyx適應症擴大帶來的更高成長潛力。Neuroguard頸動脈支架的上市也將有所貢獻,因為它是由我們的神經血管業務和周邊血管業務共同進行商業化的。
In pelvic health, we saw a slightly softer sacral nerve stimulation market environment, but look forward to seeing the increased contribution from Altaviva. In neuromodulation, we grew 4%, driven by the continued rollout of our differentiated fully-closed loop technologies Inceptiv SCS and BrainSense aDBS.
在骨盆底健康領域,我們看到骶神經刺激市場環境略顯疲軟,但期待看到 Altaviva 做出更大的貢獻。在神經調控領域,我們實現了 4% 的成長,這得益於我們差異化的全閉環技術 Inceptiv SCS 和 BrainSense aDBS 的持續推廣。
Next, our MedSearch portfolio grew 3%, endoscopy and ACM had strong quarters, endoscopy revenue grew 10%, led by mid-teens growth in our esophageal portfolio driven by Nexpowder and strong market adoption of EndoFLIP 300.
接下來,我們的 MedSearch 產品組合成長了 3%,內視鏡和 ACM 業務季度表現強勁,內視鏡收入成長了 10%,這主要得益於 Nexpowder 推動的食道產品組合實現了兩位數的成長,以及 EndoFLIP 300 的強勁市場接受度。
Acute Care & Monitoring Solutions saw a 7% growth led by strength in blood oxygen management and airway access. And finally, our surgical business grew by 1%. We saw strength and energy in wound management and hernia with expected softness and stapling. The next phase of growth for this business is the rollout of Hugo, and we're thrilled to see our first installations and first cases so swiftly after the US launch.
急性護理和監測解決方案業務成長了 7%,主要得益於血氧管理和氣道通路業務的強勁表現。最後,我們的外科手術業務成長了 1%。我們在傷口處理和疝氣手術中看到了力量和活力,以及預期的柔軟度和縫合效果。該業務的下一個成長階段是 Hugo 的推廣,我們很高興在美國推出後如此迅速地看到我們的首批安裝和首批案例。
Wrapping up our business performance is MiniMed, our diabetes business, which delivered 15% reported and over 8% organic growth. Performance was led by double-digit strength in international markets. We also saw acceleration in the US with strong sequential lift driven by Simplera Sync and Instinct, which both just launched in December.
最後要介紹的是我們的糖尿病業務 MiniMed,該業務實現了 15% 的報告成長率和超過 8% 的有機成長率。國際市場兩位數的成長帶動了整體業績的提升。我們也看到美國市場出現加速成長,這主要得益於 Simplera Sync 和 Instinct 這兩款產品在 12 月剛上市後帶來的強勁連續成長。
Our diabetes business continues its strong innovation cycle, supported by multiple recent regulatory and pipeline milestones. In addition to introducing Instinct and Simplera to the market, we secured several FDA clearances that further expand 780's indications. We also announced that 780G system is now available through pharmacy with agreements that cover the majority of commercially insured lives in the US. And we submitted MiniMed Flex to the US FDA and began the US pivotal study for [VIVERA], our third-generation fully closed loop algorithm which we believe will help maintain our leadership in delivering industry leading outcomes.
在近期多項監管和研發管線里程碑的支持下,我們的糖尿病業務持續保持強勁的創新勢頭。除了將 Instinct 和 Simplera 推向市場外,我們還獲得了多項 FDA 批准,進一步擴大了 780 的適應症。我們也宣布,780G 系統現已可透過藥局購買,相關協議涵蓋了美國大多數商業保險投保人。我們已向美國 FDA 提交了 MiniMed Flex,並開始了 [VIVERA] 的美國關鍵性研究。 VIVERA 是我們第三代全閉環演算法,我們相信它將有助於我們保持業界領先的地位,提供業界領先的治療效果。
Finally, our MiniMed Fit patch pump remains on track, and we intend to submit it to the US FDA by this fall. The planned separation of MiniMed is perfectly on track. Our preferred path continues to be a two-step, IPO and split. We continue to expect the separation to be complete by the end of calendar year '26.
最後,我們的 MiniMed Fit 貼片幫浦專案進展順利,我們計劃在今年秋季之前提交給美國 FDA。MiniMed的分拆計畫進展順利。我們首選的方案仍然是分兩步驟:IPO 和拆分。我們仍預計到 2026 年底,分離工作將完成。
Now turning to the financials.
現在來看財務數據。
This quarter, revenue of $9 billion grew 8.7% reported, and 6% organic, a 50-basis-point acceleration from prior quarter, and 50-basis-points above our guidance. Geographically, this performance was balanced, led by high-single-digit growth in Western Europe, with mid-single-digit growth across the US and Japan. US growth was 6% year over year, the strongest performance we've delivered since fiscal year 2019, excluding COVID comps.
本季營收為 90 億美元,報告成長率為 8.7%,有機成長率為 6%,比上一季提高了 50 個基點,比我們的預期高出 50 個基點。從地理來看,這一表現較為均衡,西歐實現了高個位數成長,美國和日本實現了中等個位數成長。美國市場年增 6%,這是自 2019 財年以來我們取得的最強勁的業績(不包括新冠疫情的影響)。
In China, we delivered low-single-digit growth while navigating ongoing but manageable volume-based procurement in a few businesses. Excluding VBP, our growth rate in China was mid-single-digit. Our adjusted gross margin was 64.9%, ahead of expectations.
在中國,我們在少數業務中實現了個位數低成長,同時應對了持續但可控的基於數量的採購。剔除VBP後,我們在中國的成長率為個位數中段。調整後的毛利率為 64.9%,超出預期。
As I've done in the last several quarters, let me walk you through the rough breakout of the components.
就像我過去幾季所做的那樣,讓我帶你大致了解各個組成部分。
We realized 30 basis points of benefit from pricing. Net of inflation cost down was negative 20 basis points as the third quarter is typically our lowest quarter for generating cost efficiency savings, and we had some prior nonrecurring items. Mixed was negative 100 basis points, mostly driven by class and diabetes.
我們從定價中獲得了 30 個基點的收益。在扣除通貨膨脹成本後,淨成本下降了 20 個基點,因為第三季度通常是我們實現成本效益節約的最低季度,而且我們之前還有一些非經常性項目。混合指數下跌 100 個基點,主要受階級和糖尿病的影響。
As discussed in prior disclosures with CAS in the early stages of launch, this business is currently impacted by the mix of lower margin capital to higher margin catheters, and diabetes is in the -- in its early manufacturing ramp up of Simplera. Over time, as you know we expect this mixed dynamic to improve as we scale CAS and separate the diabetes business.
正如先前在 CAS 早期上市階段所揭露的那樣,該業務目前受到低利潤率資本產品與高利潤率導管產品組合的影響,而糖尿病業務正處於 Simplera 的早期生產爬坡階段。如您所知,隨著 CAS 規模的擴大和糖尿病業務的剝離,我們預計這種混合動態將會改善。
Tariffs impacted the business $93 million or 110 basis points, in line with forecast. And finally, foreign exchange provided an approximate 40 basis points tailwind. Adjusted R&D was 8% of revenue and the increased 7.4%. On an organic basis, this outpaced revenue by 50 basis points. Adjusted SG&A was 32.3% of revenue which is 30 basis points lower than the third quarter of last year. We continue to fuel our PFA launch and develop and build the markets for Symplicity, Altaviva, and Hugo but at the same time we deliver disciplined leverage in G&A.
關稅對公司業務造成了 9,300 萬美元或 110 個基點的影響,與預期相符。最後,外匯匯率提供了約 40 個基點的利多。經過調整後的研發費用佔營收的 8%,成長了 7.4%。以有機成長計算,這一增速比營收高出 50 個基點。經調整後的銷售、一般及行政費用佔收入的 32.3%,比去年第三季下降了 30 個基點。我們繼續推進 PFA 的推出,並為 Symplicity、Altaviva 和 Hugo 開發和建立市場,但同時,我們在 G&A 方面實現了嚴格的槓桿作用。
Our adjusted operating profit was $2.2 billion resulting in an adjusted operating margin of 24.1% ahead of expectations again. Our adjusted tax rate was 17.3%, about 100 basis points higher than forecast, largely due to jurisdictional mix of profits. All in all, adjusted EPS was $1.36, $0.03 above the midpoint of our guidance range. In the fourth quarter, we expect revenue growth similar to Q3, so around 6% of a stronger Q4 '25 comp.
我們調整後的營業利潤為 22 億美元,調整後的營業利益率為 24.1%,再次超出預期。我們調整後的稅率為 17.3%,比預期高出約 100 個基點,這主要是由於利潤在不同司法管轄區的組合造成的。總而言之,調整後的每股收益為 1.36 美元,比我們預期範圍的中點高出 0.03 美元。我們預計第四季營收成長將與第三季類似,比 2025 年第四季強勁的同比數據成長約 6%。
Moving down the P&L, we expect our fiscal '26 gross margin to increase slightly, ex-tariffs. Pricing, FX, and COGS efficiency programs are expected to more than offset the negative impacts of business mix, primarily from CAS and diabetes. We anticipate a tariff impact to COGS of approximately $185 million, including $75 million in the fourth quarter. Including tariffs, we expect fiscal '26 gross margin decrease of roughly 30 basis points.
從損益表來看,我們預計 2026 財年的毛利率(不計關稅)將略有上升。定價、外匯和銷售成本效率計劃預計將抵消業務組合的負面影響,主要來自 CAS 和糖尿病。我們預計關稅將對銷售成本產生約 1.85 億美元的影響,其中第四季將產生 7,500 萬美元的影響。計入關稅後,我們預計 2026 財年毛利率將下降約 30 個基點。
We expect fiscal '26 adjusted operating profit to grow approximately 5% or 7% excluding tariffs. Our fiscal '26 operating margin is expected to be roughly flat, excluding tariffs, and down about 50 basis points, including the tariff impact. In totality, we expect these results to deliver gross margin and operating margin leverage, ex-tariffs in the second half of the fiscal year '26, as we stated last quarter.
我們預計 2026 財年調整後營業利潤(不計關稅)將成長約 5% 或 7%。預計我們 2026 財年的營業利潤率(不計關稅)將大致持平,而計入關稅影響後,營業利潤率將下降約 50 個基點。總體而言,我們預計這些業績將在 2026 財年下半年實現毛利率和營業利潤率的提升(不計關稅),正如我們上個季度所述。
Turning to EPS, this quarter we saw a beat of $0.03. This was largely due to slightly better than expected revenue in the quarter, mainly from CRM and ACM. This was partially offset by the aforementioned tax pressure that we saw in the quarter. As we expect CRM and ACM to normalize and the tax pressure to carry into Q4, we are maintaining our fiscal '26 EPS guidance in the range of $5.62 to $5.66.
本季每股收益超出預期0.03美元。這主要是由於本季營收略優於預期,主要來自客戶關係管理(CRM)及應用內容管理(ACM)業務。這部分被本季我們看到的上述稅收壓力所抵銷。由於我們預計 CRM 和 ACM 將恢復正常,且稅收壓力將持續到第四季度,因此我們維持 2026 財年每股收益預期在 5.62 美元至 5.66 美元之間。
Look, we're excited about the quarter and we think Q4 is going to be another robust quarter and that we will sustain our growth at a higher level and into the next year. We're making progress on margin expansion, and the (technical difficulty) they're going to get better. We're going to continue to invest in growth areas like R&D, sales and marketing, and M&A to capitalize on the opportunities ahead of us. And we will also continue to drive efficiency in functional areas. All told, we are committed to our guidance and we maintain our expectation for high-single-digit EPS growth in fiscal year '27.
我們對本季充滿信心,認為第四季將又是一個強勁的季度,我們將保持更高的成長水平,並延續到明年。我們在擴大利潤率方面取得了進展,(技術難題)也會得到改善。我們將繼續投資於研發、銷售和行銷以及併購等成長領域,以抓住未來的機會。我們將持續提高各職能領域的效率。總而言之,我們堅持我們的業績指引,並維持對 2027 財年每股收益實現高個位數成長的預期。
Back to you, Geoff.
傑夫,該你了。
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Okay, thanks, Thierry.
好的,謝謝你,蒂埃里。
Now, before we go to Q&A, let me close with a few final thoughts.
在進入問答環節之前,我想最後再補充幾點想法。
So we're encouraged by the progress across the business as Thierry just said and we remain committed to stronger, durable revenue and earnings growth. Our PFA trajectory is strong and we're progressing on multiple-billion-dollar opportunities. We're reinforcing our future pipeline and we're committed to organic and inorganic investment to further bolster the portfolio. Bottom line, we are delivering.
正如蒂埃里剛才所說,我們對公司各方面的進展感到鼓舞,我們將繼續致力於實現更強勁、更持久的收入和獲利成長。我們的PFA發展勢頭強勁,我們正在推動數十億美元的投資機會。我們正在加強未來的專案儲備,並致力於透過有機成長和無機成長來進一步增強投資組合。總之,我們正在準時交貨。
Now to our Medtronic colleagues around the world, thank you for your unwavering commitment to our mission and to the patients we serve. You're delivering for customers and for patients, and you're turning our strategy into performance. So thank you.
現在,我要感謝世界各地的美敦力同事們,感謝你們對我們的使命和我們所服務的病人始終如一的奉獻。你們為客戶和患者帶來了實實在在的好處,並將我們的策略轉化為實際成果。所以,謝謝你。
With that, let's turn to Q&A.
接下來,我們進入問答環節。
So first, Ingrid, welcome to your first earnings call. And now can you please provide the instructions and queue up the analysts?
首先,英格麗德,歡迎參加你的第一次財報電話會議。現在請您提供操作說明並安排分析師排隊等候?
Ingrid Goldberg - Vice President Investor Relations
Ingrid Goldberg - Vice President Investor Relations
(Event Instructions)
(活動須知)
Travis Steed, Bank of America.
特拉維斯·斯蒂德,美國銀行。
Travis Steed - Analyst
Travis Steed - Analyst
I guess first I will start on just the comments on accelerating revenue growth next year and growing earnings, high single digits. When you think about CAS (technical difficulty), obviously -- can you hear me okay?
我想先就明年加速營收成長和實現高個位數獲利成長發表評論。當你想到CAS(技術難題)時,很明顯——你能聽清楚我說話嗎?
Can you hear me okay?
你聽得清楚我說話嗎?
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
There we go.
好了。
Travis Steed - Analyst
Travis Steed - Analyst
Okay, I just wanted to ask about the accelerating revenue growth for next year, and also the commitment to grow earnings as high single digits. I guess when you think about the overall portfolio, obviously CAS is starting to hit tougher comps and just trying to think about how you get that business, accelerating with Hugo and just like the commitment to be able to deliver on the commitments that you've kind of laid out for FY27.
好的,我只是想問一下明年營收加速成長的情況,以及實現獲利高個位數成長的承諾。我想,當你考慮整個投資組合時,很明顯,CAS 開始面臨更嚴峻的競爭,你只是在思考如何獲得業務,加速 Hugo 的發展,以及履行你為 2027 財年制定的承諾。
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Well, thanks Travis for the question. I'll give it a start and then hand it over to Thierry.
謝謝特拉維斯的提問。我先開始,然後交給蒂埃里。
I mean, look, on the top-line, obviously as you mentioned, we had a really strong quarter with CAS, we think that growth is going to continue and become a larger part of the company. Obviously, we're well positioned there. And then our other big growth drivers, particularly, Symplicity for hypertension and Altaviva for overactive bladder, we see them beginning to kick in here, even in Q4.
我的意思是,你看,就營收而言,顯然正如你所提到的,我們的CAS業務在本季度表現非常強勁,我們認為這種成長勢頭將會持續下去,並成為公司更大的組成部分。顯然,我們在那裡佔據了有利位置。此外,我們的其他主要成長動力,特別是用於治療高血壓的 Symplicity 和用於治療膀胱過度活動的 Altaviva,我們看到它們開始發揮作用,甚至在第四季度也是如此。
And then you've got a number of other businesses here that are going to start growing faster than they have been here recently. One is CST, with the Stealth AXiS. I'm sure we'll get some questions on that, but I do think this is kind of underappreciated, quite frankly, by the street. This is not just a new robot. It's not just an extension of Mazor, it's a whole new platform, that has a lot of benefits to it, and I think that's going to create growth for the short and long term for CST.
此外,這裡還有許多其他企業,它們的成長速度將比最近一段時間快得多。其中一家是 CST,配備 Stealth AXiS。我相信我們會收到一些關於這方面的問題,但坦白說,我認為這一點在街頭巷尾算是被低估了。這不僅僅是一個新機器人。它不僅僅是 Mazor 的延伸,而是一個全新的平台,它有很多優勢,我認為這將為 CST 帶來短期和長期的成長。
And then neurovascular is going to kick up as well. Neurovascular has got a number of new products, like the Onyx indication for MMAe as well as our carotid stenting product and Neuroguard. And then it's anniversaries, VBP and a few other things. So you're going to see a kick up in neurovascular as well. So I think, we feel good about the growth, continuing here out, not just in Q4, but out in the FY27.
然後神經血管系統也會開始出現問題。Neurovascular 推出了一系列新產品,例如用於治療 MMAe 的 Onyx 產品,以及我們的頸動脈支架產品 Neuroguard。然後還有周年紀念日、VBP 以及其他一些事情。所以神經血管疾病也會增加。所以我認為,我們對目前的成長勢頭感到樂觀,這種成長勢頭不僅在第四季度,而且在 2027 財年也將持續下去。
Thierry Pieton - Chief Financial Officer, Executive Vice President
Thierry Pieton - Chief Financial Officer, Executive Vice President
And on the EPS side. So as I mentioned in the comments, the algorithm is clear, right? So we have the accelerated growth, the things are getting better at the gross margin level, in particular in the second half, as we'll see the mixed effect from CAS getting better and the separation of diabetes will continue to drive the leverage on the functional areas, in particular in G&A. And we'll continue to invest in R&D and in M&A. So we're reiterating the high-single-digit EPS growth guidance for '27. We do have a couple meaningful puts and takes in the number next year.
還有每股收益方面。正如我在評論中提到的,演算法很清晰,對吧?因此,我們看到了加速成長,毛利率水準的情況正在好轉,尤其是在下半年,因為我們將看到 CAS 的混合效應有所改善,糖尿病的分離將繼續推動對職能領域的槓桿作用,尤其是在一般及行政費用方面。我們將繼續增加對研發和併購的投入。因此,我們重申 2027 年每股盈餘成長接近兩位數的預期。明年我們對這個數字確實有一些重要的買入和賣出操作。
And as we're getting more visibility, we'll keep you posted on what the impacts are but, to name a few, so we'll have the carryover from the tariffs element going into next year. This year we had about 2.5 quarters of tariffs and that will carry over into the full year. I think the way to think about that is about $75 million per quarter. So on a full-year basis, it means around $300 million of our headwind versus the $185 million we're having in '26. We'll have a little bit of help from the fact that there's 53 weeks in fiscal year '27 as opposed to 52 usually.
隨著我們對情況了解更多,我們會及時向您通報其影響,例如,關稅因素的影響將延續到明年。今年我們有大約 2.5 個季度的關稅,這將延續到全年。我認為應該這樣理解:大約每季7500萬美元。因此,以全年計算,這意味著我們將面臨約 3 億美元的不利因素,而 2026 年我們將面臨 1.85 億美元的不利因素。2027 財年有 53 週,而通常只有 52 週,這會為我們帶來一些幫助。
And then, the diabetes deal. We fully expect the deal to be accretive, but between the moment we do the IPO and the moment we do the split, you should expect some dilution to the tune of $0.01 to $0.02 per month. The reason behind that is that most of the stock, the Medtronic stock retirement that we will do that drives the accretion, happens only upon the full separation. And so we'll see the accretion later, but initially, we've got a little bit of pressure coming from that.
然後,就是糖尿病問題。我們完全預期這筆交易會帶來收益成長,但從我們進行 IPO 到進行股票分割之間,您應該會預期每月會有 0.01 至 0.02 美元的股權稀釋。背後的原因是,我們將要進行的推動股價上漲的大部分美敦力股票回購,只有在完全分拆後才會發生。所以,我們稍後會看到吸積過程,但最初,我們會感受到來自那裡的一點壓力。
And we've also embedded in the guidance $0.04 to $0.05 of dilution coming from M&A activity. So we've already announced CathWorks and Anteris, and so we've embedded that in the guidance. So it's all in as we get more visibility to the timing of diabetes and the closing of the M&A deals, we'll give you more specifics on the different impacts in the Q4 release. But as you can see, we're committed to the growth acceleration. We're committed to the investment with M&A and with R&D, and we're committed to the guidance.
此外,我們還在業績指引中計入了併購活動帶來的 0.04 至 0.05 美元的稀釋。我們已經宣布了 CathWorks 和 Anteris 的計劃,並且已經將其納入了指導方針中。所以,隨著我們對糖尿病的發生時間和併購交易完成有更清晰的了解,我們將在第四季度報告中提供更多關於不同影響的具體資訊。但正如你所看到的,我們致力於加速成長。我們致力於透過併購和研發進行投資,並且我們致力於履行指導方針。
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
(multiple speakers) Go ahead, Travis.
(多人發言)請講,崔維斯。
Travis Steed - Analyst
Travis Steed - Analyst
(multiple speakers) excluding. Yeah, there's an extra selling week next year. Is that -- is the growth acceleration excluding that extra selling day?
(多位發言者)除外。是的,明年會多出一週的促銷時間。也就是說,成長加速是否不包括那額外的銷售日?
Thierry Pieton - Chief Financial Officer, Executive Vice President
Thierry Pieton - Chief Financial Officer, Executive Vice President
So that'll be part of it. That'll be part of it. And again, we'll give you the details of the impacts as we go into the Q4 announcement.
所以這也會是其中的一部分。那將是其中的一部分。此外,我們將在第四季財報發佈時詳細說明這些影響。
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
When I think about the growth acceleration, you mentioned CAS in Q3. I mean, beyond CAS you saw our CRM business and our peripheral vascular health business both step up in Q3. Q4, like I said, and beyond, CS -- think about CST and neurovascular, starting to accelerate. And then as you get into FY27, that's when the Ardian and Altaviva really kick in and also Hugo. So we feel good about that acceleration.
當我想到成長加速時,你提到了第三季的CAS。我的意思是,除了 CAS 之外,您還可以看到我們的 CRM 業務和周邊血管健康業務在第三季度都取得了成長。正如我所說,第四季及以後,CS——想想CST和神經血管,開始加速發展。然後到了 2027 財年,Ardian、Altaviva 和 Hugo 就真正開始發揮作用了。所以我們對這種加速感到滿意。
Ingrid Goldberg - Vice President Investor Relations
Ingrid Goldberg - Vice President Investor Relations
Vijay Kumar, Evercore.
Vijay Kumar,Evercore。
Vijay Kumar - Equity Analyst
Vijay Kumar - Equity Analyst
Thank you, Ingrid, and welcome to your inaugural earnings call here. Hi, Geoff, congrats on a nice sprint.
謝謝英格麗德,歡迎參加你的首次財報電話會議。嗨,Geoff,恭喜你這次衝刺表現出色。
I had one product question and one clarification on the guidance. On the product, you mentioned Ardian, Altaviva, but those will be growth accelerators in '26. How should we monitor the progress rate? Are there any goalposts that we can look forward to in tracking the launch curves for Ardian and Altaviva?
我有一個產品問題和一個關於使用指南的疑問。關於產品,你提到了 Ardian 和 Altaviva,但這些產品將在 2026 年成為成長加速器。我們該如何監控進度?在追蹤 Ardian 和 Altaviva 的上市曲線時,我們有哪些可以期待的目標?
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
It's a good question. I think we will start to lay out more concrete goalposts as we go forward. Right now, we have been talking a lot about the leading indicators that we are seeing with both and we are seeing really strong leading indicators like with Altaviva, we talked about training 500-plus physicians, strong demand training 500-plus physicians. And, like I said, last quarter, I mean, these are -- this is over the weekend, often traveling. It just shows the commitment here.
這是個好問題。我認為隨著工作的推進,我們會開始設定更具體的目標。目前,我們一直在討論我們看到的領先指標,我們看到了一些非常強勁的領先指標,例如 Altaviva,我們談到了培訓 500 多名醫生,對培訓 500 多名醫生有強勁的需求。而且,就像我之前說的,上個季度,我的意思是,這些都是——這通常是在周末,經常出差。這正體現了他們的決心。
And then things like in renal denervation, I'd say it's things like the opening of new accounts. Like this quarter, we opened 200 -- over 200 new accounts. It's a hard -- it's a high bar to get in. You have to do five cases and plus opt-in. So there's a lot more physicians doing cases today. And we'll continue to track like the covered lives like in for reimburse -- for already and -- we're already up to like 100 million covered lives, which is about third of the of the population here in the US. So those are all leading indicators and we'll start putting more other -- as you put goalposts out there as this starts to mature a little bit, both of these launches. I don't know if you have anything to add to that.
而像腎臟去神經支配之類的事情,我認為就好比開設新帳戶一樣。與本季一樣,我們開設了 200 多個新帳戶。進入這個行業門檻很高。你需要完成五個案例,外加選擇加入。所以現在做手術的醫生多了許多。我們將繼續追蹤參保人數,以便進行報銷——目前我們已經涵蓋了約 1 億參保人數,約占美國人口的三分之一。所以這些都是領先指標,隨著這兩項產品發表逐漸成熟,我們將開始設定更多其他目標。我不知道你還有什麼要補充的。
Vijay Kumar - Equity Analyst
Vijay Kumar - Equity Analyst
Great, I just one clarification on the extra week, Geoff. We're looking at exit rates of 6% organic, right, and let's assume next year is north of 6%. The extra week is almost 2 points of growth. So are we looking at base organic, excluding extra weeks, somewhere in the 5%-ish range or any thoughts on how to think about extra week contribution?
太好了,傑夫,關於多出來的一周,我還有一個問題要確認。我們看到的是 6% 的自然退出率,對吧?假設明年會超過 6%。多出來的一週時間,成長了將近 2 個點。所以我們是在考慮基本有機成長(不包括額外周數)嗎?大概在 5% 左右?或是額外週數的貢獻,大家有什麼想法嗎?
Thierry Pieton - Chief Financial Officer, Executive Vice President
Thierry Pieton - Chief Financial Officer, Executive Vice President
So maybe I'll take that one and thanks for the question. Look, first, it's a little bit less than 2 points of full growth and again, we'll give you the specific calculations as we close the year, but the way to think of it is that there's going to be growth acceleration excluding the extra week, right? So it should be upside. So we should have better growth than we have in fiscal year '26 in '27 and the extra weeks should be on top of that.
那我或許會選那個,謝謝你的提問。首先,這比完全成長少了不到 2 個百分點,我們會在年底給出具體的計算結果,但你可以這樣理解:如果排除額外的一周時間,增長速度將會加快,對吧?所以應該是向上。因此,2027 財年的成長應該會比 2026 財年更好,而且額外的幾週時間應該會在此基礎上有所提升。
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Is that clear, Vijay?
明白了嗎,維傑?
Ingrid Goldberg - Vice President Investor Relations
Ingrid Goldberg - Vice President Investor Relations
Larry Biegelsen, Wells Fargo.
拉里·比格爾森,富國銀行。
Larry Biegelsen - Analyst
Larry Biegelsen - Analyst
Geoff, I wanted to ask about CAS and your growth, continued to accelerate this quarter to 80% worldwide, which implies the worldwide EP market grew about 20% in calendar year Q4. So my question is, how are you thinking about the EP market growth in calendar year '26 and your cash growth, going forward now that you're lapping the affair US launch. I think to achieve the trailing 12 month, $2 billion goal, it looks like your CAS growth has to kind of sustain about 80%, the next two quarters. Is that directionally accurate?
Geoff,我想問關於CAS和你們的成長情況,本季全球成長持續加速至80%,這意味著全球EP市場在日曆年第四季成長了約20%。所以我的問題是,您如何看待 2026 年的 EP 市場成長以及您未來的現金成長,尤其是在您即將在美國推出產品的情況下。我認為,要實現過去 12 個月 20 億美元的目標,你們的 CAS 成長率在接下來的兩個季度必須保持在 80% 左右。方向準確嗎?
Thanks for taking the question.
感謝您回答這個問題。
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Well, first, I'd say you're -- we agree with you on the market growth in our fiscal Q3 or Q4 here of around 20%. And we think the market will continue to be like that in the near term and for our fiscal '27, we think it's going to be at least high-teens, and then thereafter a strong double-digit market. So we see the market growth continuing. And then, we believe we are really well positioned with our portfolio of catheters that we have as well as mapping.
首先,我想說——我們同意你對我們第三或第四財季市場成長約 20% 的看法。我們認為,短期內市場將持續維持這種趨勢,對於 2027 財年,我們認為至少會達到十幾個百分點,之後市場將強勁成長至兩位數。因此,我們看到市場成長動能將持續下去。而且,我們相信憑藉我們擁有的導管產品組合以及繪圖技術,我們處於非常有利的地位。
In terms of our business growth, we do see it sustaining here in Q4 and we haven't provided guidance beyond that. But, again I'd like to say, I think we're very well positioned here. When you look at the four players in PFA, I think, you got two that are really, their value proposition right now is sending around mapping, and we feel like we're very well positioned against them cause the -- we still think the catheter carries the day and we have integrated mapping. And then when you look at our competitor that's really their value proposition centers around catheters, we believe we have a better portfolio of catheters.
就我們的業務成長而言,我們預計第四季將保持成長勢頭,但我們沒有提供更遠期的業績指引。但是,我再次強調,我認為我們目前處境非常有利。當你觀察 PFA 中的四家公司時,我認為,其中兩家公司目前的價值主張是發送映射信息,而我們感覺我們與他們相比處於非常有利的地位,因為我們仍然認為導管才是關鍵,而且我們已經整合了映射功能。然後,當你看看我們的競爭對手,他們的價值主張主要集中在導管上,我們相信我們擁有更好的導管產品組合。
Our Sphere-9 is, like I said in the commentary, proven to be quite versatile. And I know initially, our competitor here did a pretty good job of putting out a narrative that Sphere-9 was more of a niche, and I think that's gotten out there that's proven not to be true as it's being used in across persistent and paroxysmal. It's new cases, redos. It's simple versus complex. It's being used across the board.
正如我在評論中所說,我們的 Sphere-9 已被證明用途非常廣泛。我知道,最初我們的競爭對手成功地營造了一種氛圍,即 Sphere-9 更像是一種小眾產品,但我認為這種說法已經被證明是不正確的,因為它已被用於治療持續性和陣發性疼痛。是新案例,也是重做案例。這是簡單與複雜的差異。它已被廣泛使用。
And then we've got Sphere-360, it's got CE marked, and it's a single-shock catheter and again, that's probably the one catheter that's got more excitement than Sphere-9 and we started the US trial. And then, of course, we're going to have mapping upgrades on a regular basis. So, I'm feeling pretty good about our position today as well as tomorrow. And like I said, the underlying market's really strong.
然後我們推出了 Sphere-360,它獲得了 CE 認證,是一款單次電擊導管,而且,這可能是比 Sphere-9 更令人興奮的導管,我們已經開始了美國試驗。當然,我們也會定期進行地圖升級。所以,我對我們今天和明天的情況都感覺相當樂觀。正如我所說,基礎市場非常強勁。
Ingrid Goldberg - Vice President Investor Relations
Ingrid Goldberg - Vice President Investor Relations
Patrick Wood, Morgan Stanley.
派崔克‧伍德,摩根士丹利。
Patrick Wood - Analyst
Patrick Wood - Analyst
I'll keep it to one just given there's so much going on. Obviously, the CathWorks and the Anteris deals. I know you were close to CathWorks for a long time. How we think about capital allocation M&A. There's a lot of other companies doing very large deals in the space, and I'm just trying to work out. Directionally, do you guys feel still more that it's kind of bolt-on M&A technology tuck-ins, that kind of things relative to larger deals, and how do you think about capital allocation going forward? Thanks.
鑑於事情太多,我就只說一件吧。顯然,指的是 CathWorks 和 Anteris 的交易。我知道你和 CathWorks 的關係一直很密切。我們如何看待資本配置併購。還有很多其他公司在這個領域進行非常大的交易,我只是想弄清楚是怎麼回事。從方向來看,你們是否仍覺得這更像是附加式的併購技術整合,相對於大型交易而言,你們如何看待未來的資本配置?謝謝。
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Well, thanks for the question, Patrick.
謝謝你的提問,派崔克。
And like as we've stated, we're very committed to accelerating M&A and you're starting to see that with CathWorks and Anteris. And again, it's very focused, tied to our strategy, venture investments that might lead to ultimately to M&A and then M&A. And we are focused on more like what we would define as tuck-in deals. They can get up to several-billion dollars, but tuck-in in or a close adjacency to our existing business and a number of them though.
正如我們之前所說,我們致力於加速併購,而 CathWorks 和 Anteris 的併購就反映了這一點。而且,它非常注重重點,與我們的策略緊密相關,即創投最終可能導致併購,然後再進行併購。我們更關注的是類似我們所說的「附加交易」。它們可以獲得高達數十億美元的資金,但它們只能依附於我們現有的業務或與其緊密相鄰,而且數量還不少。
I mean, that's the other thing. I think it's a fairly, meaningful amount of capital among several different tuck-in op -- venture and tuck-in opportunities across our portfolio. Again, prioritizing maybe the higher growth areas. And in some cases, maybe having multiple shots on goal like we did with pulsed field ablation, right? We had an organic program, we went out and got Affera. You may see us do that again in some of these high-growth really must-win markets where -- but that's how I would say it. Tuck-in across many of our different segments and sub-segments as well as venture.
我的意思是,還有另一件事。我認為這是我們投資組合中幾個不同的補充投資機會(包括創投和補充投資機會)中相當可觀的資金數量。再次強調,或許應該優先考慮成長速度更快的領域。在某些情況下,或許可以像我們之前用脈衝場消融術那樣,進行多次射門,對吧?我們有一個有機種植計劃,我們去引進了Affera。你可能會看到我們在一些高成長、必須取勝的市場中再次這樣做——但我就是這麼說的。在我們的許多不同細分市場和子細分市場以及風險投資中融入。
Patrick Wood - Analyst
Patrick Wood - Analyst
Appreciate it. Thanks for taking the question, guys.
謝謝。謝謝各位回答這個問題。
Robbie Marcus - Analyst
Robbie Marcus - Analyst
(technical difficulty) Great, can you hear me okay?
(技術故障)好的,你能聽清楚我說話嗎?
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Yes.
是的。
Robbie Marcus - Analyst
Robbie Marcus - Analyst
Two for me, maybe I'll ask them just as one.
對我來說是兩個,也許我會只問一個。
Geoff or maybe Thierry, as you think about the fiscal '27 guidance, and especially, I imagine you'll have Hugo and renal denervation and tibial spend to support those launches and continued investment in CAS. How do you think about getting to the high-single-digit EPS growth. If you could give us some high level drivers there.
Geoff 或 Thierry,在考慮 2027 財年績效指引時,我猜你們會有 Hugo、腎臟去神經術和脛骨手術方面的支出,以支持這些計畫的啟動和對 CAS 的持續投資。您認為如何才能實現接近兩位數的每股盈餘成長?如果您能給我們一些高水準的司機就太好了。
And then second part, if the street's sitting at 8.5% EPS growth, I know traditionally you do something like 6.5% to 9.4% is high single. Do you think the street at 8.5% is at a good midpoint of the range to start here? Thanks a lot.
其次,如果華爾街預期每股盈餘成長率為 8.5%,我知道傳統上你會把 6.5% 到 9.4% 當作一個較高的單年成長率。你認為目前8.5%的利率是適當的起始點嗎?多謝。
Thierry Pieton - Chief Financial Officer, Executive Vice President
Thierry Pieton - Chief Financial Officer, Executive Vice President
Hi, Robbie. Thanks for the question. So again, on EPS, the high-level drivers, we talked about the accelerated growth and obviously that's going to help from a leverage standpoint. If you look at the gross margin line, what you've seen so far is operational improvements in pricing and cost out that have been offset by the mixed effects on CAS and diabetes. And as I've stated a couple of times already, those are going to get better. So the CAS improvement comes from the mix shifting towards more catheters and less capital equipment, which will help from a margin perspective. And then on the diabetes side, it comes from the separation, right? So diabetes has a lower gross margin rate than the rest of the business. And so once that business go away, it'll give us a natural lift from a gross margin perspective.
嗨,羅比。謝謝你的提問。所以,再說一遍,關於每股盈餘,我們談到了高層次的驅動因素,即加速成長,這顯然會從槓桿角度有所幫助。如果你看一下毛利率這條線,你會發現目前為止,定價和成本控制方面的營運改善被 CAS 和糖尿病帶來的複雜影響所抵消。正如我之前多次提到的,這些情況都會好轉的。因此,CAS 的改進來自於導管使用量增加、資本設備使用量減少的組合變化,這將有助於提高利潤率。而糖尿病方面,則是源自於分離,對吧?因此,糖尿病業務的毛利率低於其他業務。因此,一旦這部分業務消失,從毛利率的角度來看,自然會為我們帶來提升。
If you start looking at overhead. Look, we're going to continue to lean into R&D and sales and marketing to develop the franchises that you mentioned. So we're putting resources in Ardian, we're putting resources in CAS. We're hiring the mappers that are necessary. We're doing the direct-to-consumer marketing on, in particular on renal denervation and Altaviva, and we'll continue to do that.
如果你開始關注開銷。你看,我們將繼續加大研發、銷售和行銷力度,以發展你所提到的那些特許經營業務。所以我們正在向 Ardian 投入資源,我們也正在向 CAS 投入資源。我們正在招募所需的地圖繪製人員。我們正在進行直接面向消費者的行銷活動,特別是針對腎臟去神經術和 Altaviva,我們將繼續這樣做。
But, net-net, the SG&A line will provide leverage because we -- as we're having this quarter, for example, or Q3, what you see is the leverage that we get on the G&A line more than offsets the resources that we're putting from our sales and marketing perspective. So look, that will provide some improvements on operating margin and then, below the line, we'll continue to have a little bit of a headwind on the interest line because we're refinancing debt that was contracted almost at 0%, four or five years ago, with debt that's now at sort of 3.5%, 4%, and we'll continue to have some pressure on tax, but the tax line is kind of getting to (technical difficulty) now.
但總的來說,銷售、一般及行政費用將提供槓桿作用,因為——例如,正如我們本季度或第三季度的情況一樣,你會看到,我們在一般及行政費用中獲得的槓桿作用超過了我們在銷售和營銷方面投入的資源。所以你看,這將對營業利潤率帶來一些改善,但另一方面,由於我們正在對四五年前幾乎以 0% 利率簽訂的債務進行再融資,而現在的債務利率約為 3.5% 或 4%,因此我們在利息方面仍會面臨一些不利因素。此外,我們將繼續面臨一些稅收壓力,但稅收方面現在已經有點(技術性困難)了。
And then look, I mentioned we have a few puts and takes where we need to understand the timing between now and your ends. One is the timing of the diabetes separation. And as I said, between the IPO and the split, we get about $0.01 to $0.02 of dilution from the fact that we're losing 20% of the profit of diabetes, but we don't have the benefit from the share count reduction yet. That share count reduction is calculated on a 12-month rolling average, so you'll see that gradually get better. And then we'll have some dilution coming from M&A. So, the guidance is all in at a high-single-digit EPS growth.
然後你看,我提到過,我們有一些買賣交易需要了解從現在到你最終目標之間的時間安排。一是糖尿病分離的時間。正如我所說,在首次公開募股和股票分割之間,由於我們失去了糖尿病業務 20% 的利潤,我們每股收益將稀釋約 0.01 至 0.02 美元,但我們尚未從股份數量減少中受益。該股數量減少量是按 12 個月滾動平均值計算的,因此你會看到情況逐漸好轉。然後,併購還會帶來一些股權稀釋。因此,業績指引全部集中在高個位數的每股盈餘成長。
Now, the second part of your question on the 8.5%, it feels like some of the latter items that I mentioned, so the sort of temporary dilution that we get from diabetes and some of the M&A dilution is maybe not fully embedded in what the Street sees right now and as we get more visibility, we'll help clarify that.
現在,關於您問題的第二部分,也就是 8.5% 的部分,感覺就像我之前提到的一些因素,例如糖尿病帶來的暫時性稀釋以及一些併購稀釋,可能還沒有完全被華爾街所理解,隨著我們獲得更多信息,我們會幫助澄清這一點。
Ingrid Goldberg - Vice President Investor Relations
Ingrid Goldberg - Vice President Investor Relations
Matt Taylor, Jefferies.
馬特泰勒,傑富瑞集團。
Matthew Taylor - Equity Analyst
Matthew Taylor - Equity Analyst
I wanted to follow-up on the question around capital allocation and TAVR. I guess it was interesting to see the investment in Anteris. I was wondering if you could comment about why you didn't just buy the whole company versus invest, and we also saw over the weekend the results of the longer-term follow-up for CORBEL published in [JAK]. And similar to the Edwards trials, there was some late catch up in mortality. I was wondering if you could comment in the TAVR.
我想就資本配置和TAVR的問題進行後續探討。我覺得看到 Anteris 的投資挺有趣的。我想請您解釋一下,為什麼您沒有直接收購整個公司,而是選擇了投資。另外,我們週末也看到了CORBEL長期追蹤研究的結果。[JAK]。與愛德華茲試驗類似,死亡率在後期出現了一些上升。我想問您是否可以對TAVR發表一些評論。
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Sure, I think, on your first call in Anteris. I mean, we feel the Structural Heart space is one of the spaces we helped pioneer. We have a really strong position, great reputation, but we want to expand in that. We've got some organic programs. Obviously, we have our Evolut platform. We've got mitral and tricuspid replacement programs, but we still think there's an opportunity here to expand. In the case of TAVR, the balloon expandable is the larger piece of the market, and this is an opportunity to get into that market. Again, we may have multiple shots on goal here, but I think Anteris is a good one to invest in and partner with and we'll see where we go from here to there.
當然,我想,在你第一次使用Anteris時就可以了。我的意思是,我們認為結構性心臟領域是我們幫助開創的領域之一。我們擁有非常強大的市場地位和良好的聲譽,但我們希望在此基礎上進一步擴張。我們有一些有機種植項目。當然,我們也有自己的 Evolut 平台。我們有二尖瓣和三尖瓣置換項目,但我們仍然認為這裡還有擴展的機會。就經導管主動脈瓣置換術 (TAVR) 而言,球囊擴張式主動脈瓣膜佔據了更大的市場份額,這是一個進入該市場的機會。我們或許會有多次射門機會,但我認為安特里斯是一家值得投資和合作的公司,我們拭目以待。
And then in terms of the JAK article, I would say here that, look, this is -- I just want to emphasize that this is an old valve that's no longer commercially available and it's an old procedural technique that we've provided guidance. So basically, all that communication did is reiterate the guidance that we provided back in 2020. And so, that's what's happening there and like I said, we're collaborating with our physicians to make sure they understand all of this and moving forward from here. So that's -- if you have anything to add there.
至於 JAK 文章,我想強調的是,這是一個已經不再商業銷售的舊閥門,而且這是一種我們已經提供指導的舊手術技術。所以基本上,所有這些溝通只是重申了我們在 2020 年提供的指導。所以,這就是那裡正在發生的事情,就像我說的,我們正在與醫生合作,確保他們了解這一切,並以此為基礎繼續前進。所以,如果你還有什麼要補充的的話。
But bullish on the Structural Heart space and I would -- the Anteris Investment and who knows, maybe more following that.
但我看好結構性心臟領域,我會投資 Anteris,誰知道呢,也許之後還會投資更多。
Ingrid Goldberg - Vice President Investor Relations
Ingrid Goldberg - Vice President Investor Relations
Matt Miksic, Barclays.
馬特·米克西奇,巴克萊銀行。
Matt Miksic - Analyst
Matt Miksic - Analyst
Congrats on the Anteris Investment, by the way.
順便恭喜你投資了Anteris。
So on CAS, I'll just ask one question. You mentioned generator sales or kind of a headwind to gross margins at this point, the mix is maybe shifting a little more towards the capital. You give us a sense of when that starts to normalize.
所以,在CAS上,我只問一個問題。您提到發電機銷售目前對毛利率構成了一定阻力,產品組合可能正向資本產品傾斜。你讓我們感受到這種情況何時開始正常化。
And then also in terms of the runway, and I think we understand that hiring mappers is maybe the bottleneck here, if they, if you want to put it that way. You need more people to open more centers to get more catheter use. Any sense of where you are in that continuum through the academic centers or into the general centers in the US and some sense of the pace that you're able to maintain for hiring centers. So helpful color. Appreciate you taking the question.
此外,就跑道而言,我認為我們明白,招聘地圖繪製員可能是這裡的瓶頸,如果你要這麼說的話。你需要更多的人開設更多的中心,才能提高導尿管的使用率。了解你在美國學術中心或普通招募中心所處的階段,以及你在招募中心能夠維持的進度。顏色真好用。感謝您回答這個問題。
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Thanks, Matt. On the last part of it, where are we? I still think we're kind of relatively early in our launch here. We still have a long runway to go, which is good in penetrating some of these high volume academic centers as well as getting out beyond that.
謝謝你,馬特。最後一部分,我們講到哪裡了?我仍然認為我們目前的推廣還處於相對早期階段。我們還有很長的路要走,這有利於我們打入一些高流量的學術中心,並進一步擴展業務。
And, to your point, the mappers -- hiring mappers has been critical. It's not the topic if you will, but it is an important topic here. We've been able to stay ahead of it, but it is the thing that we're probably the most focused on right now is continuing to hire mappers. And a lot of these mappers tend to be pretty dedicated to this space and they're seeing where the direction of travel is or to use a Minnesota term, where the puck's going. And so that helps a lot as well. So that's how I would comment on there and what was the first part of the question?
正如您所說,地圖繪製人員—聘請地圖繪製人員至關重要。雖然這不是我們討論的主題,但在這裡它是一個重要的話題。我們一直能夠領先一步,但目前我們最關注的事情可能是繼續招募地圖繪製人員。許多地圖繪製者都對這個領域非常投入,他們正在觀察發展的方向,或是用明尼蘇達州的說法,觀察冰球的運行軌跡。所以這也有很大幫助。這就是我對這個問題的評論,那麼問題的第一部分是什麼?
Thierry Pieton - Chief Financial Officer, Executive Vice President
Thierry Pieton - Chief Financial Officer, Executive Vice President
The first part was on the dilution that comes from the equipment and when does the mix turn around.
第一部分是關於設備造成的稀釋以及混合物何時發生變化。
So first what I wanted to say is CAS is a fantastic business from an operating margin perspective, right? So it is slightly diluted because of this mixed issue at the GM level, but it's driving significant, profitability at the total business level at the operating margin level.
首先我想說的是,從營業利潤率的角度來看,CAS 是一家非常棒的公司,對吧?因此,由於通用汽車層面的這一複雜問題,其收益略有稀釋,但它在整體業務層面和營業利潤率層面推動了顯著的獲利能力。
When it's going to turn around between capital equipment and catheters, I want to say it's almost a good problem to have. So I hope it turns around as late as possible because as we're building the install base, it's always going to be good news going forward. That being said, I think you'll start to see an inflection in the second half of next year.
當需要在大型設備和導管之間進行權衡時,我想說這幾乎算是一個幸福的煩惱。所以我希望這種情況越晚好轉越好,因為隨著我們不斷擴大用戶基礎,這對未來的發展始終都是好消息。也就是說,我認為明年下半年將會出現轉機。
The mix is starting to improve with the catheter sales increasing, and look, year over year, CAS is going to drive gross margin improvement as early as '27. So look, it's a great business to be in and it's all good news going forward.
隨著導管銷售額的成長,產品組合開始改善,而且,從 2027 年起,CAS 將逐年推動毛利率的提高。所以你看,這是一個很棒的行業,未來一切都是好消息。
Ingrid Goldberg - Vice President Investor Relations
Ingrid Goldberg - Vice President Investor Relations
Chris Pasquale, Nephron.
克里斯·帕斯誇萊,腎臟病。
Chris Pasquale - Analyst
Chris Pasquale - Analyst
I wanted to ask about Hugo. Geoff, you talked about the impact of Symplicity and Altaviva really beginning to kick in as soon as next quarter. I don't think you included Hugo in that group, so I'd love to hear how you're thinking about the timeline for Hugo to really begin to move the needle within the surgical business and any qualitative comments you can make about the system pipeline right now.
我想問關於雨果的事。Geoff,你之前說過Symplicity和Altaviva的影響最早將在下個季度開始顯現。我認為你沒有把 Hugo 納入那個群體,所以我很想聽聽你對 Hugo 何時才能真正開始在外科手術業務中發揮重要作用的看法,以及你對目前系統流程的任何定性評論。
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Well, first of all, look, super excited about where we are with Hugo. Big quarter for us this past quarter, getting the FDA approval. We just announced this morning, we did -- we completed our first cases in the US in February, earlier this month in Cleveland Clinic. We got more scheduled this week and other centers and all the leading indicators of Hugo, and oh by the way, on those cases, we got great feedback in terms of how the system is performing and its future opportunity in the US market.
首先,說實話,我對我們和 Hugo 的合作進展感到非常興奮。上個季度對我們來說是個重要的季度,我們獲得了FDA的批准。我們今天早上剛剛宣布,我們確實完成了——我們於二月在克利夫蘭診所完成了美國的首批病例。本週我們安排了更多工作,其他中心以及所有 Hugo 的領先指標,哦,對了,關於這些案例,我們得到了很好的反饋,了解該系統的性能及其在美國市場的未來機會。
The leading indicators are all positive in terms of the smooth case rate, procedures -- procedure growth globally, and utilization. They can both continue to be really strong. We watch those every week. I know the business watches it every day. I see them every week. And we're seeing, a pretty meaningful step up in installations around the world, especially as US kicks in. And so we look, we expect to step up in Q4.
從病例進展率、手術量(全球手術量成長)和使用率來看,所有領先指標均為正態勢。他們倆都能繼續保持很強的實力。我們每週都會看。我知道企業每天都在關注這件事。我每週都能見到他們。我們看到,世界各地的安裝量都出現了相當大的成長,尤其是在美國開始安裝後。因此,我們預計第四季度業績將有所提升。
Now, the surgical business is a big business, has some puts and takes. So you may not move the needle on the surgical business quite yet, but underneath the covers there, Hugo is growing and growing pretty fast now. And it'll eventually -- you'll see, you'll start to see this move that big $6-billion business. But we like where we sit, really excited about getting into the US market and the reception that we're getting and the orders that we have.
如今,外科手術產業是一個龐大的產業,有利有弊。所以,你可能還無法在外科手術業務上取得突破,但在幕後,Hugo 正在成長,而且現在成長得相當快。最終——你會看到,你會開始看到這筆價值 60 億美元的大生意發生轉變。但我們對目前的處境感到滿意,對進入美國市場、獲得市場反應以及收到的訂單感到非常興奮。
Ingrid Goldberg - Vice President Investor Relations
Ingrid Goldberg - Vice President Investor Relations
Danielle?
丹妮爾?
Danielle Antalffy - Analyst
Danielle Antalffy - Analyst
Geoff, I was hoping you could talk a little bit more about how we should think about renal denervation, Symplicity, and the market development that you're talking about. We've talked to some referring physicians who've been involved in renal denervation since the very beginning and she sounds like she's getting a lot of calls from folks. I'm just curious what goes into actually developing this market, building out, helping centers build out referral networks, et cetera. And if you can give any color on actual numbers to date even directionally.
傑夫,我希望你能再多談談我們應該如何看待腎臟去神經支配、Symplicity 以及你所說的市場發展。我們和一些從一開始就參與腎臟去神經支配手術的轉診醫生談過,聽起來她接到了很多人的電話。我只是好奇,開發這個市場、建立市場、幫助中心建立轉診網絡等等,實際上需要哪些步驟。如果您能根據實際數字給出一些顏色,即使只是方向性的描述。
Thanks so much. Sorry about that.
非常感謝。抱歉。
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Thanks, Danielle. I mean, I appreciate that question.
謝謝你,丹妮爾。我是說,我很感謝你提出這個問題。
I mean, first of all, in terms of physicians getting a lot of calls, that is really starting to kick in. Just to give you -- again, I appreciate that it's a leading indicator, but it's pretty powerful. So on our direct-to-consumer website around Symplicity, I'm just double-checking. Last quarter, we had maybe 50,000 or Q2 rather, we had about 50,000 visits. In Q3 we had 2.5 million visits. So the consumer demand is really spiking here and we're just getting started.
我的意思是,首先,就醫生接到大量電話而言,這種情況真的開始顯現出來了。再次強調一下——我知道這只是一個領先指標,但它的確非常有效。所以,我正在我們面向消費者的網站上,也就是關於 Symplicity 的網站上,再次確認一下。上個季度,我們大概有 5 萬次訪問,或者更確切地說,第二季度我們大約有 5 萬次訪問。第三季我們獲得了 250 萬次造訪。所以,這裡的消費需求真的在激增,而我們才剛開始。
Like I said earlier, we opened up over 200 accounts, the physician finder is up, reimbursement is strong. We're getting that strong consumer demand and most importantly, we're getting, terrific patient results, patient outcomes, right, with the blood pressure coming down meaningfully. It's staying -- patients -- and it's really resonating with patients and that in and of itself is getting doctors excited.
正如我之前所說,我們已經開設了 200 多個帳戶,醫生查找器運作良好,報銷情況也很好。我們獲得了強勁的消費者需求,更重要的是,我們獲得了極佳的患者療效,血壓顯著下降。它正在被患者接受,而且真的引起了患者的共鳴,這本身就讓醫生們感到興奮。
And so what we're doing is we've been hiring a lot of people in terms of market development and there's several different roles here, right? One is building that referral pathway from the general practitioners and the hypertension -- hypertensive specialists into the hospital, into that procedural list. We've got a lot of people around health economics, around coding and billing as well as helping the hospitals, so it's a number of roles like that, right? Health economics, coding, billing as well as some of the other roles I said in terms of the market development, building those referral pathways.
所以,我們正在做的就是招募很多人從事市場開發工作,這裡有好幾個不同的職位,對吧?一是建立從全科醫生和高血壓專科醫生到醫院的轉診途徑,將高血壓患者納入手術清單。我們有很多從事衛生經濟學、編碼和計費以及幫助醫院方面的人員,所以有很多類似的職位,對吧?健康經濟學、編碼、計費以及我之前提到的市場開發、建立轉診途徑等其他一些角色。
And that's really where things are right now. I'd say all the market, like the initial foundational elements have all been like -- the chips have turned over green, right? The FDA approval is breakthrough approval and it's broad, the CMS reimbursement, it's a good number and it's broad. The commercial payers are falling in line and the competitive dynamics are way better than we thought. Initially here, we're doing, I saw different analysts, over the last couple of years, predictions on the mix between us and the other competitors on the market. We're doing way better than any of those models.
這就是目前事情的實際情況。我覺得整個市場,就像最初的基礎要素一樣,都已經──翻盤了,對吧?FDA的批准是突破性批准,而且覆蓋範圍很廣;CMS的報銷金額也很高,覆蓋範圍也很廣。商業支付方正在逐步適應,競爭格局比我們想像的要好得多。最初,我們在這裡所做的,我看到過去幾年裡,不同的分析師對我們與市場上其他競爭對手之間的關係進行了預測。我們比那些模型都做得好得多。
And so now we just got to build this market. It's all those things we said, Danielle. But again, where we're really excited, where you feel the energy is, it all starts with those patient outcomes and how this is resonating with consumers.
所以現在我們只需要建立起這個市場。丹妮爾,就是我們之前說的那些話。但話說回來,真正讓我們感到興奮、讓你感受到活力的地方,一切都始於患者的治療效果以及它如何引起消費者的共鳴。
So the other thing we're going to do over time besides building the referral pathway, working with hospitals, is building the brand around Symplicity, right? So all the 50,000 to 2.5 million I talked about of site visits, that's all about lead development, lead generation. We'd also like to build the brand of Symplicity and make it synonymous with hypertension management. So that's going to be an investment that Thierry talked about for FY27.
所以,除了建立轉診途徑、與醫院合作之外,隨著時間的推移,我們還要做的一件事就是圍繞 Symplicity 打造品牌,對吧?所以,我之前提到的 5 萬到 250 萬次的網站流量,都是關於潛在客戶開發和潛在客戶產生的。我們也希望打造 Symplicity 品牌,使其成為高血壓管理的代名詞。所以,這將是蒂埃里在2027財年提到的一項投資。
So a lot of exciting a lot of excitement right now and already, and I'll start to -- the numbers and it will be more meaningful and FY27 for us, the actual revenue, the lagging indicators. And again, it's very profitable right out of the gate for us.
所以現在有很多令人興奮的事情,而且我已經開始——這些數字對我們來說將更有意義,2027 財年的實際收入,落後指標。而且,對我們來說,它從一開始就非常有利可圖。
Ingrid Goldberg - Vice President Investor Relations
Ingrid Goldberg - Vice President Investor Relations
Joanne Weunsch, Citi.
Joanne Weunsch,花旗銀行。
And before we move to Joanne, please of course email us for any of those we did not reach today. Sorry and thank you, and we'll look forward to talking to you soon.
在聯絡喬安妮之前,當然也請今天我們未能聯絡到的各位寄email給我們。抱歉,也謝謝您,期待盡快與您聯絡。
But Joanne, please go ahead.
但是喬安妮,請繼續吧。
Joanne Wuensch - Analyst
Joanne Wuensch - Analyst
I'm going to ask the Stealth AXiS question and what you can share with us about the product and why you're so excited about it.
我接下來要問的是關於 Stealth AXiS 的問題,您能和我們分享一下關於這款產品的信息,以及您為什麼對它如此興奮嗎?
Thank you.
謝謝。
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Well, thanks, Joanne, for that question. First of all, like I said, I do think this has been -- is meaningfully underappreciated in me, not so much in maybe in the clinical community from spine surgeons, but maybe in the investment community. Because look, this robot does two things.
謝謝你,喬安妮,問了這個問題。首先,就像我剛才說的,我認為這一點一直被嚴重低估了,也許在脊椎外科醫生等臨床界人士中不是這樣,但在投資界可能不是這樣。因為你看,這個機器人可以做兩件事。
First of all, it's not an extension of Mazor. It's a new platform with a ton of new functionality, that's going to be very value-added. But the other thing that's really important here is how it fits into the workflow. So today, 70%, I mentioned in the commentary, 70% of procedures in the US are navigated. That's like navigation in OR which we invented and we lead by far. And, today, robotics doesn't work well with that workflow. So that's why robotic penetration is a lot smaller than the 70% that we're seeing with navigation.
首先,它不是 Mazor 的延伸。這是一個擁有大量新功能的全新平台,將非常有價值。但另一件非常重要的事情是它如何融入工作流程。所以今天,正如我在評論中提到的,美國 70% 的手術都是透過導航完成的。這就像運籌學中的導航技術一樣,那是我們發明的,而且我們遙遙領先。而如今,機器人技術與這種工作流程並不相容。所以這就是為什麼機器人技術的滲透率遠低於導航技術70%的滲透率的原因。
The Stealth AXiS fits right into that workflow. So it's one seamless system from the initial imaging to the AI based-surgical planning, right into the case, navigation, imaging, and now robotics, one seamless workflow that trust me, surgeons really have been waiting for. So you've got a better robot with more functionality and then you've got a much, much, much better workflow that, as you know is super important to physicians and health systems and this is just effectively lowering the barriers to step into robotics for spine surgery and it's going to grow the market, I believe, and we are definitely going to continue to take share.
Stealth AXiS 剛好契合這種工作流程。因此,從初始成像到基於人工智慧的手術規劃,再到手術、導航、成像,以及現在的機器人技術,這是一個無縫銜接的系統,一個無縫的工作流程,相信我,外科醫生們真的一直在等待這樣的工作流程。所以,你現在擁有了功能更強大的機器人,以及更有效率的工作流程。正如你所知,這對醫生和醫療系統來說至關重要。這有效地降低了脊椎手術機器人技術的門檻,我相信這將促進市場成長,我們肯定會繼續擴大市場份額。
And this really lengthens our extends, our lead, in my opinion, from our primary competitor in the space. The competitive dynamics have dramatically changed over the last couple of years. We're enabling technology and our AiBLE suite is key to winning. And this is, like I said, extends our lead over our competitor. And so, super excited about that.
在我看來,這確實拉大了我們在該領域相對於主要競爭對手的領先優勢。近兩年來,競爭格局發生了巨大變化。我們正在推動技術發展,而我們的 AiBLE 套件是致勝的關鍵。正如我所說,這進一步擴大了我們相對於競爭對手的領先優勢。所以,我對此感到非常興奮。
But in closing here, I'd say beyond some of the big, generational growth drivers we mentioned, we talked a lot about CAS and Ardian, a little bit about Altaviva and Hugo. I would add to that robotics piece. I would add, self-access. But we've got a breadth of innovation right now at Medtronic, which is why you feel -- we're getting the excitement here. Whether you saw it from this quarter, like I mentioned from CRM and peripheral vascular health, which we didn't get any questions on. Their growth has meaningfully improved here from a number of new products like carotid and thrombectomy. We talked about CST accelerating, neurovascular is accelerating with new products that they've got between the Neuroguard carotid products as well as MMAe, that's a mouthful.
但最後我想說,除了我們提到的一些重大的、世代成長驅動因素之外,我們還討論了很多關於 CAS 和 Ardian 的內容,以及一些關於 Altaviva 和 Hugo 的內容。我想補充一些關於機器人技術的內容。我還要補充一點,是自助參觀。但美敦力目前擁有廣泛的創新,這就是為什麼你會感到——我們在這裡感受到了興奮。無論你從本季是否看到,就像我提到的 CRM 和周邊血管健康方面一樣,我們沒有收到任何相關問題。他們在這裡的成長得益於頸動脈和血栓切除術等一系列新產品的推出,並取得了顯著的進展。我們談到了 CST 加速發展,神經血管領域也在加速發展,他們推出了 Neuroguard 頸動脈產品以及 MMAe 等新產品,這真是一口氣說完。
And then you've got these, like I said, these bigger growth drivers like Ardian and Altaviva that are at the very, very -- and Hugo, that are at the very early stages. So you're starting to see the breadth kick in, which is beautiful to see. I know that in this business, innovation is key, and we've got a depth of innovation with these big generational growth drivers, but we also have the breadth. And as Thierry, walked through, I think it was Robbie's question we're pulling different levers to make sure that we're investing appropriately in these organically, whether it's increasing R&D, funding direct-to-consumer, hiring a ton of mappers. And if you're a mapper out there, hit our website up, and then kicking in the M&A, right? So we're really shifting our stance, moving into more of an offensive footing here, and it's based on just the momentum that we have and the momentum we see coming.
然後,就像我剛才說的,還有一些更大的成長驅動因素,像是 Ardian 和 Altaviva,它們都處於非常非常早期的階段——還有 Hugo,它們也處於非常早期的階段。所以你開始看到視野開闊了,這真是太好了。我知道在這個產業,創新是關鍵,我們擁有深厚的創新實力,這得益於這些龐大的世代成長驅動因素,而且我們也擁有廣度。蒂埃里走過來的時候,我想羅比問的是,我們正在採取不同的措施,以確保我們對這些領域進行適當的有機投資,無論是增加研發投入、資助直接面向消費者的業務,還是僱用大量的地圖繪製人員。如果你是地圖繪製者,那就造訪我們的網站,然後開始進行併購吧?所以我們正在真正改變我們的立場,轉向更具進攻性的策略,這完全是基於我們現有的勢頭以及我們預見的未來勢頭。
Ingrid Goldberg - Vice President Investor Relations
Ingrid Goldberg - Vice President Investor Relations
All right. Thank you, everyone, and I'll turn to Geoff for some closing remarks.
好的。謝謝大家,接下來請傑夫做總結發言。
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
Geoffrey Martha - Executive Chairman of the Board, Chief Executive Officer
I thought that was the close. Okay. (laughter)
我以為比賽就此結束了。好的。(笑聲)
Thank you all for joining today, and all of your questions, and I appreciate your support and continued interest in Medtronic, and we hope that you'll join us for our Q4 and our full-year fiscal '26 earnings broadcast where we're going to update you on the continued progress that we just talked about against our short- and long-term strategies.
感謝各位今天蒞臨,感謝大家提出的所有問題。感謝大家對美敦力的支持與持續關注。我們希望大家能參加我們2026財年第四季和全年業績發表會,屆時我們將向大家匯報我們剛才提到的短期和長期策略的持續進展。
With that, have a great rest of your day. Thank you.
祝您今天餘下的時間過得愉快。謝謝。